Melatonin: A Potential Candidate for the Treatment of Experimental and Clinical Perinatal Asphyxia
Molecules · 22.01.2023 · 28 (3) · 1105
DOI: 10.3390/molecules28031105 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 22.01.2023. Verfasst von Ryszard Pluta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ecotech-Complex Analytical and Programme Centre for Advanced Environmentally-Friendly Technologies, Marie Curie-Skłodowska University in Lublin, 20-6…. Hauptthemen laut MEDLINE: Hypoxia-Ischemia, Brain, Melatonin, Hypothermia, Asphyxia Neonatorum. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Perinatal asphyxia is considered to be one of the major causes of brain neurodegeneration in full-term newborns. The worst consequence of perinatal asphyxia is neurodegenerative brain damage, also known as hypoxic-ischemic encephalopathy. Hypoxic-ischemic encephalopathy is the leading cause of mortality in term newborns. To date, due to the complex mechanisms of brain damage, no effective or causal treatment has been developed that would ensure complete neuroprotection. Although hypothermia is the standard of care for hypoxic-ischemic encephalopathy, it does not affect all changes associated with encephalopathy. Therefore, there is a need to develop effective treatment strategies, namely research into new agents and therapies. In recent years, it has been pointed out that natural compounds with neuroprotective properties, such as melatonin, can be used in the treatment of hypoxic-ischemic encephalopathy. This natural substance with anti-inflammatory, antioxidant, anti-apoptotic and neurofunctional properties has been shown to have pleiotropic prophylactic or therapeutic effects, mainly against experimental brain neurodegeneration in hypoxic-ischemic neonates. Melatonin is a natural neuroprotective hormone, which makes it promising for the treatment of neurodegeneration after asphyxia. It is supposed that melatonin alone or in combination with hypothermia may improve neurological outcomes in infants with hypoxic-ischemic encephalopathy. Melatonin has been shown to be effective in the last 20 years of research, mainly in animals with perinatal asphyxia but, so far, no clinical trials have been performed on a sufficient number of newborns. In this review, we summarize the advantages and limitations of melatonin research in the treatment of experimental and clinical perinatal asphyxia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ecotech-Complex Analytical and Programme Centre for Advanced Environmentally-Friendly Technologies, Marie Curie-Skłodowska University in Lublin, 20-612 Lublin, Poland.
- Department of Neonate and Infant Pathology, Medical University of Lublin, 20-093 Lublin, Poland.
- Laboratory of Ischemic and Neurodegenerative Brain Research, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.
ORCID-Profile: Ryszard Pluta, Agata Tarkowska
Zitieren
APA
Pluta, R., Furmaga-Jabłońska, W., Januszewski, S., & Tarkowska, A. (2023). Melatonin: A Potential Candidate for the Treatment of Experimental and Clinical Perinatal Asphyxia. Molecules, 28(3), 1105. https://doi.org/10.3390/molecules28031105
Vancouver
Pluta R, Furmaga-Jabłońska W, Januszewski S, Tarkowska A. Melatonin: A Potential Candidate for the Treatment of Experimental and Clinical Perinatal Asphyxia. Molecules. 2023;28(3):1105. doi:10.3390/molecules28031105
BibTeX
@article{Pluta2023,
author = {Pluta, Ryszard and Furmaga-Jabłońska, Wanda and Januszewski, Sławomir and Tarkowska, Agata},
title = {Melatonin: A Potential Candidate for the Treatment of Experimental and Clinical Perinatal Asphyxia},
journal = {Molecules},
year = {2023},
volume = {28},
number = {3},
pages = {1105},
doi = {10.3390/molecules28031105}
}
EUVIMED